Look for:

Our offer for

VIVORYON THERAPEUTICS AG


ISIN:
NL00150002Q7
WKN:
-

2024/04/26 17:35:27
Price
0.80 EUR
Difference -2.44% (-0.02)

General attributes

ISINNL00150002Q7
SymbolVVY
ExchangeEuronext Amsterdam
CurrencyEUR
SectorChemical / Pharmaceutical / Health
Security typeStock
Market cap (m)21 EUR
BenchmarkGERMANY DAX

Market data

Bid (Bid size)0.789 EUR (5,000)
Ask (Ask size)0.80 EUR (2,174)
Open0.826 EUR
High0.85 EUR
Low0.794 EUR
Close (prev. day)0.82 EUR
VWAP0.817849 EUR
Volume (pcs)344,230
Trading volume281,528.00
Number of trades279
Last size655

Futures and Options

Related Futures-
Related Options-

PDF Downloads

Company report: VIVORYON THERAPEUTICS AGPDF Download

Scale: ABS REL         Instrument

Add Benchmark:



Information about previous performance does not guarantee future performance.
Source: FactSet

Recent research



2024/04/26 17:35:27
Price
0.80 EUR
Difference -2.44% (-0.02)

General attributes

ISINNL00150002Q7
SymbolVVY
ExchangeEuronext Amsterdam
CurrencyEUR
SectorChemical / Pharmaceutical / Health
Security typeStock
Market cap (m)21 EUR
BenchmarkGERMANY DAX

Market data

Bid (Bid size)0.789 EUR (5,000)
Ask (Ask size)0.80 EUR (2,174)
Open0.826 EUR
High0.85 EUR
Low0.794 EUR
Close (prev. day)0.82 EUR
VWAP0.817849 EUR
Volume (pcs)344,230
Trading volume281,528.00
Number of trades279
Last size655

Performance and Risk

6m1Y3Y
Perf (%)-89.87%-94.02%-94.47%
Perf (abs.)-7.10-12.58-13.66
Beta2.941.891.20
Volatility347.76248.00150.38
Scale: ABS REL         Instrument

Add Benchmark:



Information about previous performance does not guarantee future performance.
Source: FactSet

Price data

Ø price 5 days | Ø volume 5 days (pcs.)0.76 EUR (1,677,262)
Ø price 30 days | Ø volume 30 days (pcs.)0.56 EUR (454,168)
Ø price 100 days | Ø volume 100 days (pcs.)5.40 EUR (474,664)
Ø price 250 days | Ø volume 250 days (pcs.)9.22 EUR (230,460)
YTD High | date9.93 EUR (2024/02/12)
YTD Low | date0.41 EUR (2024/04/17)
52 Weeks High | date19.56 EUR (2023/05/09)
52 Weeks Low | date0.41 EUR (2024/04/17)

All listings for VIVORYON THERAPEUTICS AG

Exchange  DateTimePriceTrading volume (mio.)Number of trades
Tradegate2024/04/2622:260.791 EUR0.0434
Stuttgart2024/04/2617:150.786 EUR0.016
Munich2024/04/2608:110.852 EUR0.002
London Stock Exchange2024/02/0216:108.313 EUR0.021
Frankfurt2024/04/2620:270.784 EUR0.001
Euronext Amsterdam2024/04/2617:350.80 EUR0.28279
Duesseldorf2024/04/2608:110.807 EUR0.003
Berlin2024/04/2621:500.791 EUR0.0017

Company Logo

https://gateway.mdgms.com/extern/logo_image.html?ID_LOGO=139179&ID_TYPE_IMAGE_LOGO=2

Contact Details

VIVORYON THERAPEUTICS NV
- -
Weinbergweg 22 - 06120 Halle
Telefon: +49-345-555-99-00
Fax: +49-345-555-99-01
E-mail: info@vivoryon.com

PDF Downloads

Company report: VIVORYON THERAPEUTICS AGPDF Download

Company Profile

Vivoryon Therapeutics NV is a biopharmaceutical company, which engages in the research and development of therapeutic products for the treatment of Alzheimer's disease. Its product pipeline includes PQ912, PBD-C06, and PQ1565. The company was founded by Hans-Ulrich Demuth and Konrad Glund on July 25, 1997 and is headquartered in Halle, Germany.

Members of Management Board

Frank WeberChairman of Managing Board
Michael SchaefferMember of Executive Committee
Anne DoeringMember of Executive Committee
Florian SchmidMember of Executive Committee

Board of directors

Erich Maximilian PlatzerChairman of Supervisory Board
Claudia RiedlMember of Supervisory Board
Michael SchaefferMember of Supervisory Board
Samir ShahMember of Supervisory Board
Anne DoeringMember of Supervisory Board
Charlotte LohmannMember of Supervisory Board





Decline
Accept

We use cookies and web analysis software to give you the best possible experience on our website. If you consent, these tools will be used. Please read more information here

INFORMATION FOR PRIVATE CLIENTS / CONSUMERS

Any information, material and services regarding financial instruments and securities provided by Česká spořitelna/Erste Group/ or any of its affiliates (collectively “Erste Group“) on this and any linked website hereafter (jointly the “Websites“) shall be exclusively to investors who are not subject to any legal sale or purchase restrictions.

By agreeing to this hereto, the visitor entering this Websites confirms that has read, understood and accepted this Information and the Disclaimer